Skip to main navigation
  • Home
  • About us
    • History
    • Management
    • Board of Directors
    • Quotations
    • Healing Gifts
  • Investors
    • Overview
    • Stock Information
    • SEC Filings
    • News Releases
    • Event Calendar
    • Webcasts & Presentations
    • Analyst Coverage
    • Corporate Governance
    • Information Request
  • Products
    • PURION ® Process
    • AmnioFix ®
    • EpiFix ®
    • OrthoFlo
    • EpiCord™
    • AmnioCord™
    • AmnioFill
    • CollaFix™
    • Patents
    • Safety/Quality Assurance/Regulatory
    • Reducing Wastage
  • Therapeutic Areas
    • Acute and Chronic Wounds
    • Sports Medicine
    • Surgical Applications
  • Education/Conferences
  • Clinical/Scientific - Health Care Professionals
    • Clinical Publications
    • Scientific Publications
    • Posters
  • Contact Us
    • Careers
  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

  • small-logo-tag

›‹
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7

Investors Menu

  • Overview
  • Stock Information
  • SEC Filings
  • News Releases
  • Events Calendar
  • Webcasts & Presentations
  • Analyst Coverage
  • Corporate Governance
  • Information Request
mimedx

Event Details

MIMEDX GROUP INC at Stifel Healthcare Conference

Nov 19, 2014 11:30 am EST

Webcast Presentation

Click here for webcast
Event Details
Title
MIMEDX GROUP INC at Stifel Healthcare Conference
Date / Time
Nov 19, 2014 11:30 am EST

Investors Menu

  • Overview
  • Stock Information
  • SEC Filings
  • News Releases
  • Events Calendar
  • Webcasts & Presentations
  • Analyst Coverage
  • Corporate Governance
  • Information Request
mimedx
news

News and Events

  • Mar 28, 2018
    Summary ToggleMiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of RMAT Designated AmnioFix® Injectable For The Treatment Of Osteoarthritis Of The Knee

    Initiation of Phase 2B Study Follows Quickly After FDA Grants RMAT Designation for Knee OA MARIETTA, Ga. , March 28, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, today announced that the first patient has been

    Read More

  • Mar 26, 2018
    Summary ToggleMiMedx To Participate In The Needham Healthcare Conference

    MARIETTA, Ga. , March 26, 2018 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), a leading developer and marketer of regenerative and therapeutic biologics, announced today that it will participate in the 17th Annual Needham Healthcare Conference in New York on Wednesday, March 28, 2018 .

    Read More

  • Mar 26, 2018
    Summary ToggleMiMedx Reports Positive Pain And Foot Function Results From Phase 2B Clinical Trial Of AmnioFix® Injectable In The Treatment Of Plantar Fasciitis

    Patients Experienced Clinically Meaningful Reduction in Pain AmnioFix Injectable Achieves Primary and Secondary Efficacy Endpoints Statistically Significant Difference in Pain and Function Compared to Placebo MARIETTA, Ga. , March 26, 2018 /PRNewswire/ -- MiMedx Group, Inc.

    Read More

Investor Toolkit

  • Print Page
  • RSS Feeds
  • E-mail Alerts
  • IR Contacts

Products

CONTACT US

888.543.1917

MiMedx® is committed to the development of new and innovative clinical and cost-effective solutions for the use of our biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. This website is not meant as a substitute for professional medical advice.

© 2017 MiMedx Group, Inc. All rights reserved. | 1775 West Oak Commons Ct. NE, Marietta, GA 30062